The market expects Biogen Inc. (BIIB) to deliver a year-over-year decline ... but a powerful factor that might influence its near-term stock price is how the actual results compare to these ...

Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Earnings Yield Investor model based on the published strategy of ...

In trading on Friday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 27.8, after changing hands as low as $123.02 per share. By comparison ...

SG Americas Securities, LLC has opened a new $98.5M position in $BIIB, per a new SEC 13F filing. This disclosure reflects the funds' holdings for the 03-31-2025 ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the May 23rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options ...

Biogen Inc. (BIIB) shares rallied 5.7% in the last trading ... estimate revisions are strongly correlated with near-term stock price movements. For Biogen, the consensus EPS estimate for the ...

The firm decreased its portfolio allocation in BIIB by 18.27% over the last quarter ... the author and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider of financial ...

Biogen BIIB announced that the FDA has granted fast track designation to its investigational Alzheimer's disease (AD) drug, BIIB080. How Does the Fast Track Tag Benefit BIIB’s Drug Development?